度普利尤单抗对斑贴试验的影响及难治性特应性皮炎中共病过敏性接触性皮炎的患病率
该回顾性图表综述纳入48例接受度普利尤单抗治疗的特应性皮炎患者,比较用药前后斑贴试验结果及共病过敏性接触性皮炎(ACD)的患病率。结果显示仅少数斑贴试验反应在度普利尤单抗治疗期间「丢失」(13/125;10.4%),91.4%的受试者存在共病ACD,且92.3%在度普利尤单抗治疗期间行斑贴试验者通过避免过敏原获得进一步临床改善。
要点
- 度普利尤单抗治疗期间斑贴试验反应丢失率低(10.4%),未见明显抑制效应。
- 难治性特应性皮炎患者中共病ACD患病率高(91.4%)。
- 避免过敏原可使度普利尤单抗治疗后未完全缓解的皮炎进一步改善(92.3%)。
核心结论
- 度普利尤单抗似乎不对斑贴试验结果产生抑制效应。
- 特应性皮炎共病过敏性接触性皮炎高度流行,避免过敏原可显著改善度普利尤单抗治疗后未消退的残留皮炎。
研究设计与样本
- 回顾性图表综述,纳入48例接受度普利尤单抗治疗的特应性皮炎患者。
- 比较度普利尤单抗启用前后进行的斑贴试验结果及接受斑贴试验者中共病ACD的患病率。
主要发现
- 少数斑贴试验反应在度普利尤单抗治疗期间「丢失」(13/125;10.4%)。
- 13个丢失反应中5个发生于有明确免疫缺陷记录的个体。
- 92.3%在度普利尤单抗治疗期间行斑贴试验的个体通过避免过敏原获得进一步临床改善。
关键数值与推荐
- 斑贴试验反应丢失率:13/125(10.4%)。
- 避免过敏原后进一步临床改善比例:92.3%。
临床怎么用
- 对度普利尤单抗治疗后仍有残留皮炎的特应性皮炎患者,可考虑行斑贴试验以排查共病过敏性接触性皮炎。
- 度普利尤单抗治疗期间斑贴试验结果仍具参考价值,但需注意免疫缺陷患者可能出现反应丢失。
- 检出过敏原后指导避免接触有助于进一步改善残留皮炎。
局限性
- 非随机化研究,队列样本量小。
- 度普利尤单抗的清除通过患者主观报告评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether the type 2 T helper cell-specific immunosuppressive action of dupilumab interferes with patch testing. OBJECTIVES: We sought to evaluate the reliability of patch testing on dupilumab and the contribution of allergic contact dermatitis (ACD) to complex dermatitis in patients with residual dermatitis on dupilumab. METHODS: This is a retrospective chart review of 48 patients with atopic dermatitis (AD) who were treated with dupilumab. We compare the results of patch tests performed before and after the initiation of dupilumab and the prevalence of comorbid ACD in patch-tested individuals. RESULTS: A minority of patch test reactions were "lost" on dupilumab (13/125; 10.4%). Five of 13 lost reactions occurred in individuals with documented immunodeficiency. Thirty-two of 35 patch-tested patients (91.4%) had comorbid ACD; 92.3% of individuals patch tested on dupilumab experienced further clinical improvement with allergen avoidance. LIMITATIONS: This is a nonrandomized study in a small cohort of patients. The clearance of dupilumab was assessed by subjective patient reports. CONCLUSIONS: Dupilumab does not appear to exert a dampening effect on patch test results. AD with comorbid ACD was highly prevalent and allergen avoidance resulted in significant improvement in residual dermatitis that had not resolved without dupilumab therapy.
引用
- Raffi J, Suresh R, Botto N, et al. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review. J Am Acad Dermatol. 2019. PMID: 31562940. doi:10.1016/j.jaad.2019.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。